CVTX - CV Therapeutics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (80)	5/30/2003 7:03:33 PM
From: Miljenko Zuanic	of 411

Thanks WE, (LLC) <<The =2.9 msec mean increase in QT interval…>> So, why was there concern in first place? What is QTc interval and confidence level for alfuzosin? “To date, drugs that prolong the mean QT/QTc interval by 5-10 msec under conditions of maximum effect have also not been clearly associated with risk. Drugs causing a mean 10-20 msec increase under conditions of maximum effect are of concern, but have been approved if they appear to have important therapeutic roles. Drugs that prolong the mean QT/QTc interval by >20 msec have a substantially increased likelihood of being proarrhythmic, and may have clinical arrhythmic events captured during drug development.”” As I did mentioned early QTc for Ran is not concern, interval is 3-10 msec. Only very few have >500 msec, no difference from placebo. Obviously, market like very much this news. However, and for record, my concern (also mentioned early) was and is not Ran QTc. It is TTS small exercise duration difference from placebo and possibility that pFOX may influence weight gain in diabetic population? Miljenko

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next